342.46
price down icon0.74%   -2.54
 
loading
Beone Medicines Ltd Adr stock is traded at $342.46, with a volume of 155.73K. It is down -0.74% in the last 24 hours and up +10.11% over the past month. Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.
See More
Previous Close:
$345.00
Open:
$342.37
24h Volume:
155.73K
Relative Volume:
0.54
Market Cap:
$37.89B
Revenue:
$4.98B
Net Income/Loss:
$69.60M
P/E Ratio:
658.83
EPS:
0.5198
Net Cash Flow:
$525.67M
1W Performance:
+1.87%
1M Performance:
+10.11%
6M Performance:
+14.53%
1Y Performance:
+53.32%
1-Day Range:
Value
$341.52
$351.39
1-Week Range:
Value
$328.91
$353.00
52-Week Range:
Value
$196.45
$385.22

Beone Medicines Ltd Adr Stock (ONC) Company Profile

Name
Name
Beone Medicines Ltd Adr
Name
Phone
41-616851900
Name
Address
C/O BEONE MEDICINES I GMBH, BASEL
Name
Employee
11,000
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
ONC's Discussions on Twitter

Compare ONC with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ONC
Beone Medicines Ltd Adr
342.42 38.18B 4.98B 69.60M 525.67M 0.5198
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
464.91 119.76B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
762.75 79.35B 14.34B 4.50B 3.88B 41.57
Biotechnology icon
ARGX
Argen X Se Adr
845.87 51.71B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
347.05 44.80B 3.21B 43.57M 221.36M 0.2405

Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-24-25 Initiated Truist Buy
Sep-18-25 Initiated Barclays Overweight
Apr-07-25 Initiated RBC Capital Mkts Outperform
Mar-03-25 Upgrade BofA Securities Neutral → Buy
Dec-03-24 Resumed Morgan Stanley Overweight
Sep-18-24 Initiated JMP Securities Mkt Outperform
Feb-06-24 Resumed JP Morgan Overweight
Sep-12-23 Initiated Macquarie Outperform
Aug-17-23 Initiated Jefferies Buy
Jul-17-23 Initiated Citigroup Buy
Jun-30-23 Downgrade Bernstein Outperform → Mkt Perform
Jan-12-23 Initiated Daiwa Securities Buy
Oct-13-22 Upgrade Guggenheim Neutral → Buy
Oct-13-22 Upgrade SVB Leerink Mkt Perform → Outperform
Aug-09-22 Resumed JP Morgan Overweight
Mar-17-22 Downgrade SVB Leerink Outperform → Mkt Perform
Feb-07-22 Initiated Deutsche Bank Buy
Oct-12-21 Initiated Bernstein Outperform
Oct-06-21 Upgrade CLSA Underperform → Buy
Mar-08-21 Initiated China Renaissance Buy
Mar-01-21 Downgrade CLSA Outperform → Underperform
Nov-09-20 Downgrade Ladenburg Thalmann Buy → Neutral
Nov-06-20 Downgrade Maxim Group Buy → Hold
Nov-06-20 Downgrade Piper Sandler Neutral → Underweight
View All

Beone Medicines Ltd Adr Stock (ONC) Latest News

pulisher
Feb 02, 2026

BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Sees Significant Decline in Short Interest - MarketBeat

Feb 02, 2026
pulisher
Feb 02, 2026

3 Stocks to Buy in February - Finviz

Feb 02, 2026
pulisher
Jan 31, 2026

Wall Street Bullish on BeOne Medicines AG (ONC) amid Robust Pipeline Development - Finviz

Jan 31, 2026
pulisher
Jan 31, 2026

Mirae Asset Global Investments Co. Ltd. Acquires 38,992 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat

Jan 31, 2026
pulisher
Jan 30, 2026

Citizens Highlights BeOne Medicines' (ONC) $3.8B Revenue Potential for 2025 - Finviz

Jan 30, 2026
pulisher
Jan 30, 2026

BeOne Medicines Collaboration Extends Safety Modeling As Shares Trade Below Targets - Sahm

Jan 30, 2026
pulisher
Jan 29, 2026

FDA Accepts Summit's Lung Cancer Drug Application, Review Underway - Benzinga

Jan 29, 2026
pulisher
Jan 28, 2026

Assessing BeOne Medicines (ONC) Valuation After Expanded InSysBio Collaboration On Clinical Trial Modeling - Sahm

Jan 28, 2026
pulisher
Jan 24, 2026

Did BeOne’s New Uptrend And Upgraded Earnings Outlook Just Shift Its (ONC) Investment Narrative? - simplywall.st

Jan 24, 2026
pulisher
Jan 24, 2026

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Jan 24, 2026
pulisher
Jan 24, 2026

EMCOR Group, Inc. (NYSE:EME) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World

Jan 24, 2026
pulisher
Jan 24, 2026

Financial Review: Atossa Genetics (NASDAQ:ATOS) versus ADM Tronics Unlimited (OTCMKTS:ADMT) - Defense World

Jan 24, 2026
pulisher
Jan 22, 2026

BeOne Medicines (NASDAQ:ONC) Shares Gap DownShould You Sell? - MarketBeat

Jan 22, 2026
pulisher
Jan 22, 2026

BeOne Medicines Earnings Momentum Spurs Valuation Debate And Analyst Optimism - Sahm

Jan 22, 2026
pulisher
Jan 21, 2026

Five Below Upgraded, Spotify Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Jan 21, 2026
pulisher
Jan 21, 2026

BEONE MEDICINES LTD-ADR (NASDAQ:ONC) Passes Minervini Trend Template and Strong Growth Scan - Chartmill

Jan 21, 2026
pulisher
Jan 18, 2026

CICC Predicts HSI to Add ZIJIN GOLD INTL/ BEONE MEDICINES/ PICC P&C/ AKESO as New Constituents; STANCHART May Replace HANG SENG BANK - AASTOCKS.com

Jan 18, 2026
pulisher
Jan 17, 2026

Assessing BeOne Medicines (ONC) Valuation After A Year Of Strong Shareholder Returns - Sahm

Jan 17, 2026
pulisher
Jan 15, 2026

HERIZON-GEA-01 Phase 3 Zanidatamab Combo Data Might Change The Case For Investing In BeOne Medicines (ONC) - Sahm

Jan 15, 2026
pulisher
Jan 11, 2026

Chan Henry Lee Sells 664 Shares of BeOne Medicines (NASDAQ:ONC) Stock - Defense World

Jan 11, 2026
pulisher
Jan 10, 2026

JGP Global Gestao de Recursos Ltda. Decreases Stock Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat

Jan 10, 2026
pulisher
Jan 10, 2026

Fingerlakes Wealth Management Inc. Has $6.96 Million Holdings in Schwab U.S. Large-Cap Growth ETF $SCHG - Defense World

Jan 10, 2026
pulisher
Jan 09, 2026

BeOne Medicines (NASDAQ:ONC) SVP Chan Henry Lee Sells 664 Shares - MarketBeat

Jan 09, 2026
pulisher
Jan 08, 2026

Snowline Gold (CVE:SGD) Shares Up 3% – Here’s What Happened - Defense World

Jan 08, 2026
pulisher
Jan 07, 2026

Is the Options Market Predicting a Spike in BeOne Medicines Stock? - Yahoo Finance

Jan 07, 2026
pulisher
Jan 04, 2026

BrightSpire Capital (NYSE:BRSP) Shares Gap Down – Here’s What Happened - Defense World

Jan 04, 2026
pulisher
Dec 31, 2025

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Dec 31, 2025
pulisher
Dec 26, 2025

Voya Investment Management LLC Raises Holdings in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat

Dec 26, 2025
pulisher
Dec 19, 2025

John Oyler Sells 75,631 Shares of BeOne Medicines (NASDAQ:ONC) Stock - Defense World

Dec 19, 2025
pulisher
Dec 18, 2025

BeOne Medicines appoints Dr. Lai Wang as president and global head of R&D - Investing.com

Dec 18, 2025
pulisher
Dec 17, 2025

BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 24,369 Shares - MarketBeat

Dec 17, 2025
pulisher
Dec 16, 2025

BeOne Medicines (NASDAQ:ONC) Shares Gap Down After Insider Selling - Defense World

Dec 16, 2025
pulisher
Dec 15, 2025

BeOne Medicines (NASDAQ:ONC) Shares Gap Down Following Insider Selling - MarketBeat

Dec 15, 2025
pulisher
Dec 15, 2025

Ford Upgraded, Amazon Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Dec 15, 2025
pulisher
Dec 14, 2025

LMR Partners LLP Acquires New Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat

Dec 14, 2025
pulisher
Dec 14, 2025

China Universal Asset Management Co. Ltd. Makes New Investment in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat

Dec 14, 2025
pulisher
Dec 13, 2025

BeOne Medicines (NASDAQ:ONC) SVP Sells $107,900.00 in Stock - MarketBeat

Dec 13, 2025
pulisher
Dec 13, 2025

35,910 Shares in BeOne Medicines Ltd. – Sponsored ADR $ONC Purchased by Axa S.A. - Defense World

Dec 13, 2025
pulisher
Dec 13, 2025

Bellevue Group AG Makes New $9.37 Million Investment in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat

Dec 13, 2025
pulisher
Dec 12, 2025

35,910 Shares in BeOne Medicines Ltd.Sponsored ADR $ONC Purchased by Axa S.A. - MarketBeat

Dec 12, 2025
pulisher
Dec 12, 2025

Lee Chan Henry, SVP at BeOne Medicines, sells shares worth $213,568 - Investing.com

Dec 12, 2025
pulisher
Dec 11, 2025

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases Shares of 9,377 BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat

Dec 11, 2025
pulisher
Dec 10, 2025

12,338 Shares in BeOne Medicines Ltd. – Sponsored ADR $ONC Purchased by American Century Companies Inc. - Defense World

Dec 10, 2025
pulisher
Dec 10, 2025

8,037 Shares in BeOne Medicines Ltd.Sponsored ADR $ONC Acquired by Guggenheim Capital LLC - MarketBeat

Dec 10, 2025
pulisher
Dec 10, 2025

First Trust Advisors LP Makes New Investment in BeOne Medicines Ltd. – Sponsored ADR $ONC - Defense World

Dec 10, 2025
pulisher
Dec 10, 2025

First Trust Advisors LP Makes New Investment in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat

Dec 10, 2025
pulisher
Dec 10, 2025

12,338 Shares in BeOne Medicines Ltd.Sponsored ADR $ONC Purchased by American Century Companies Inc. - MarketBeat

Dec 10, 2025
pulisher
Dec 08, 2025

Temasek Holdings Private Ltd Acquires New Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat

Dec 08, 2025
pulisher
Dec 08, 2025

Nan Fung Group Holdings Ltd Makes New $3.81 Million Investment in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat

Dec 08, 2025
pulisher
Dec 08, 2025

Jump Financial LLC Invests $17.02 Million in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat

Dec 08, 2025
pulisher
Dec 08, 2025

Russell Investments Group Ltd. Acquires Shares of 13,603 BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat

Dec 08, 2025

Beone Medicines Ltd Adr Stock (ONC) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Beone Medicines Ltd Adr Stock (ONC) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Lee Chan Henry
SVP, General Counsel
Jan 07 '26
Sale
331.76
664
220,289
0
OYLER JOHN
Chief Executive Officer
Dec 15 '25
Sale
307.79
75,631
23,278,679
24,369
OYLER JOHN
Chief Executive Officer
Dec 16 '25
Sale
302.87
24,369
7,380,739
0
$155.33
price up icon 0.83%
$347.19
price up icon 2.35%
$106.79
price down icon 2.19%
$844.50
price up icon 1.06%
$32.95
price down icon 0.90%
Cap:     |  Volume (24h):